French connection: NDA Group opens Parisian office

NDA Group, European drug development consultancy, has opened a new office in Paris, France, to serve its growing customer base in the country and continue its global expansion.

This new office will be the fifth for the group to be housed within Europe. Other offices are located in Stockholm, London, Munich and Zürich.

“NDA has had close relationships with many of the drug developing companies in France and French speaking Europe for many years. I am therefore delighted to finally be able to announce the opening of our new offices in one of the most prominent capitals of the EU,” commented Johan Strömquist, CEO of NDA Group. “NDA having a presence in Paris is important to our French clients and other drug development companies in the area. It gives faster access to our great pool of expertise and makes it even easier to communicate across the borders. Ultimately I believe this will help French companies develop their products even better than today and reach the patients they're targeting even faster.”

This latest expansion comes shortly after the company revealed significant growth within the US. The Parisian office will serve as a platform for NDA Group’s customers to not only be able to access Europe but also the US.

“We are so excited about our new office. The Paris office provides a critical location in Europe to service a range of biotech and pharmaceutical companies within France and environs that are easily accessed from this international hub,” added Dr Laurie Smaldone Alsup, MD, CSO and COO of NDA Group. “We will begin with direct business development and outreach to make our global services and our amazing people known to a broader client base.”

Dr Mira Pavlovic-Ganascia, HTA expert at NDA Group and deputy director for Health Technology Assessment at the Hauté Autorité de Santé (HAS) stated: “NDA, bienvenue à Paris. Big and small companies and current and future partners in France and from French speaking neighbour countries are sure to benefit from support in our domains of excellence — regulatory and HTA — to rapidly bring medicines to the world.”